Navigation Links
MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA
Date:12/14/2010

world for a total of 2,500 to 3,000 patients. Over 1,000 MPS IVA patients worldwide have been identified through The International Morquio Organization (IMO) survey and the BioMarin MorCAP registry program.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its program for MPS IVA, and particularly the timing and conduct of clinical trials related thereto, and expectations regarding filings with regulatory agencies. These forward-looking statements ar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Based ... closure market, Frost & Sullivan recognises Incisive Surgical ... for Customer Value Leadership. Incisive Surgical,s uniquely-designed, innovative ... technology that eliminates the need for patients to ... and staple removal  that may result in increased ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... HARTLAND, Wis., Aug. 30, 2011 H&P Industries, Inc., ... hiring of Eamonn Vize to fill the Chief Operating ... 20 years of experience in the Pharmaceutical and Biotechnology ... provide his knowledge of Pharmaceutical Operations and Validations to ...
... , a leading supplier of embedded technologies, products, and ... embedded computers to a medical original equipment ... of the six-month contract is about 1.5M USD. ... will allow the customer to meet market demand and ...
Cached Medicine Technology:Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application 2
(Date:9/16/2014)... McLean, Va. (PRWEB) September 16, 2014 ... use through predictive analytics and targeted clinical programs, ... The announced changes support the Company’s drive to ... analytics and targeted clinical programs. On September 2, ... parent company, Millennium Health, announced that RxAnte founder ...
(Date:9/16/2014)... News) -- Illegal drug use among teens in the United ... report. Encouragingly, the new study also found that ... among young people between the ages of 12 and 17 ... of 70,000 people aged 12 and older across the United ... abuse problems among this age group also dropped from 8.9 ...
(Date:9/16/2014)... YORK, NY (September 16, 2014) The Columbia ... the 2014 Higher Education Excellence in Diversity (HEED) ... and largest diversity-focused publication in higher education. As ... honor recognizing U.S. colleges and universities that demonstrate ... be featured along with 82 other recipients in ...
(Date:9/16/2014)... September 15, 2014A prospective study that compared patient-reported ... with bone metastases demonstrates that single fraction radiation ... fraction radiation therapy (MFRT) when pain, function and ... presented today at the American Society for Radiation ... indicates that improvements in patients, pain, function and ...
(Date:9/16/2014)... September 16, 2014 Fresh shiitake ... iron and potassium. They are second-most consumed mushroom ... and their healing and health properties. , In ... Shiitakes can stimulate and strengthen the immune system ... contain polycharrides, including beta glucans . These ...
Breaking Medicine News(10 mins):Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3
... ULURU Inc. (NYSE AMEX: ULU ) ... 31, 2009. The Company reported a net loss of $3.1 ... $1.8 million, or $0.03 per share, for the same period last ... cash equivalents of $5.1 million, compared with $7.6 million at December ...
... Calif., May 15 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... former chief operating officer of Boston Scientific, to its ... shareholders at the company,s annual shareholders, meeting on May ...
... Richard Boland, M.D., chief of gastroenterology at Baylor ... vice president of the American Gastroenterological Association (AGA) Institute, ... 2011. The oldest medical specialty society in the United ... and practice of gastroenterology. AGA membership includes 16,500 physicians ...
... & PARIS, FRANCE The International Union for ... Public Health Education (SOPHE) are pleased to release today ... standards and quality assurance systems of global capacity in ... Health Education & Behavior (Vol. 36, No. 3, ...
... of Ultrasound in Medicine is pleased to announce the ... All operators of ultrasound systems with an output display ... consists of 3 parts: Bioeffects and Biophysics, Prudent Use, ... the information from this 64 page publication, users can ...
... Group, Inc. (Nasdaq: NYER ) reported results for ... for third quarter of fiscal 2009 increased $1.3 million or ... the comparable quarter in the prior year. The increase ... new pharmacies over the past 12 months. Revenues slightly ...
Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 6Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 2Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 3Health News:Dallas Gastroenterologist Named Vice President of Prestigious National Organization 2Health News:Special journal issues released on global health promotion and health education 2Health News:AIUM releases second edition of 'Medical Ultrasound Safety' 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 3Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 4Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 5
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: